Adolor Disbands Entereg Sales Force Following Second 'Approvable' Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm plans to submit complete response to FDA in Q2 2007.
You may also be interested in...
Wyeth/Progenics Oral Methylnaltrexone Pushed Back A Year To Test New Formula
Companies expect to submit an NDA for the oral formulation to treat opioid-induced constipation in 2009/2010 after initiating a new Phase II trial.
Wyeth/Progenics Oral Methylnaltrexone Pushed Back A Year To Test New Formula
Companies expect to submit an NDA for the oral formulation to treat opioid-induced constipation in 2009/2010 after initiating a new Phase II trial.
GSK/Adolor Entereg “Approvable” Pending CV Risk Data
FDA’s second “approvable” letter for the postoperative ileus treatment requests development of a risk management plan and 12-month safety data from an ongoing trial.